STOCKS TELEGRAPH

Tag: CVM stock

  • Is There Any Reason As To Why The CVM Stock Plunged In Premarket Session?

    Is There Any Reason As To Why The CVM Stock Plunged In Premarket Session?

    At last check, CEL-SCI Corporation (CVM) shares were down -5.65% to trade at $8.19 in pre-market trading. During Wednesday’s trading session, CEL-SCI stock rose 8.50% to $8.68. CVM stock volume was 7.55 million shares, compared to the one million shares averaged over the past 50 days. In the past week, CVM shares have moved down by -32.35%. The company’s shares have fallen by -37.01% over the last 12 months.

    Over the past three months, shares have fallen -46.72%, while over the last six months they fell -30.67%. A total of 40.05 million shares were outstanding as of the end of June, with the market capitalization of CVM standing at $398.67 million. CVM’s stock has been losing ground even after it sent a letter to shareholders clarifying the confusion surrounding one of its studies.

    What did CVM write to shareholders?

    CEL-SCI believes that encouraging an immune system boost while it is still intact will provide the greatest benefit to a patient. Thus, in the Phase 3 study, CVM used its investigational product Multikine first and BEFORE surgery and radiotherapy, or surgery and concurrent radiotherapy and chemotherapy, for those newly diagnosed with advanced primary squamous cell carcinoma of the head and neck. With its unique approach, CVM stands out from the competition. For patients receiving Multikine plus radiation and surgery, the study demonstrated excellent survival results. The survival benefit was negated when chemotherapy was added.

    CEL-SCI sent out a shareholder letter yesterday to clarify some confusion about CVM’s Phase 3 study results announced last week.

    Here are some highlights of the letter:

    • As a result of CVM’s Multikine immunotherapy, the world’s largest Phase 3 study of newly diagnosed advanced primary head and neck cancer demonstrated a statistically significant survival benefit of 14.1% after receiving surgery and radiotherapy.
    • A CVM study involves about 155,000 patients per year and 40% of the total study population.
    • CVM noted that there appears to be confusion concerning whether data from one of the 2 potential treatment arms is adequate for approval despite the fact that it shows benefits for its patients.
    • As explained by CVM, the protocol stipulated that the analysis for the successful treatment arm must be conducted before the unblinding.
    • CVM can use this data to seek FDA approval for its successful treatment.
    • This data has been reviewed by CVM and deemed safe, and it knows that it can be used in seeking FDA approval based on this data.
    • CVM’s Phase 3 results showed that this treatment arm’s overall survival (OS) benefit was robust and durable for five years, without any safety issues, something that is uncommon for cancer drugs.
    • At 5-years, Multikine-treated patients had a 14.1% absolute advantage over the unknown control group in overall survival, according to CVM.

    How CVM is planning to move forward?

    CEL-SCI (CVM) announced results from a Phase 3 study on June 28, 2021, which showed that Multikine achieved all of the protocol requirements stated in the study protocol in patients receiving surgery and radiation as their standard therapies. CVM will apply for and seek FDA approval to use Multikine in this patient population for the treatment of advanced primary head and neck cancer.

  • CEL-SCI Corp. (CVM) Stock Prices on the Rise Following Continued Development of Multikine

    CEL-SCI Corp. (CVM) Stock Prices on the Rise Following Continued Development of Multikine

    CEL-SCI Corp. (CVM) stock prices were up by 5.20% as of the market closing on June 25th, 2021, bringing the price per share up to USD$25.08 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 7.42%, bringing it up to USD$26.94.

    Bought Deal

    June 11th, 2021 saw the company announce its entering into an underwriting agreement with Kingswood Capital Market. As per the agreement, the underwriter made a purchase of 1.4 million shares of CVM’s common stock. Each share was priced at USD$22.62, with gross proceeds amounting to USD$31.7 million before the deduction of expenses related to the offering. The agreement also included a 30-day option for underwriters to purchase up to an addition 210,000 shares to cover over-allotments.

    MultikineTrial

    December 2020 saw the company’s Phase 3 head and neck cancer study complete database lock and enter the statistical analysis phase. Independent contractors have been hired to conduct the analysis process so as to ensure CVM stays blind to the study data. The company hopes to meet FDA safety and efficacy requirements, with the statistical analysis plan following the protocol states objectives. Furthermore, the company is keen to compile the clinical benefits the Multikine has the potential to provide patients that are newly diagnose, but not yet treated, for advanced primary squamous cell carcinoma of the head and neck.

    Multikine Production Facility

    With the commercial launch of Multikine looming closer, CVM has been allocating resources towards the expansion and upgrading of its proprietary cGMP manufacturing facility for Multikine. Construction began in 2020, with completion anticipated for the next several months. Upon completion, the company plans to double the facility’s capacity to accommodate two shifts for maximum production of Multikine.

    Financial Reports

    The six month period ended March 2021 saw the company report an operating loss of USD$17.3 million, up from the USD$13.6 million reported for the six month period ended March 31st, 2020. Operating loss for the quarter ended March 31st, 2021 was USD$8.5 million, up from the USD$6.7 million reported for the same time period of the prior year. The six and three-month periods ended March 31st, 2021, respectively reported USD$6.9 million and USD$3.3 million in capitalized costs.

    Future Outlook for CVM

    Armed with the nearing commercialization of Multikine, CVM is poised to continue its trajectory of success by allocating resources towards Multikine’s proliferation in the U.S and global markets. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • The CEL-SCI Corporation (CVM) stock has been rallying for the past week; here’s why

    The CEL-SCI Corporation (CVM) stock has been rallying for the past week; here’s why

    In the current trading session, CEL-SCI Corporation (CVM) stock surged by 20.45% to the price of $24.15 at the time of writing. CVM stock closed Wednesday’s session at $20.05 which is a gain. The stock volume traded today for 6.17 million shares. The shares exchanged hands five times the average volume of trade for the past 3 months. For the past year, CVM stock soared by 75.42%, and the past week it had also jumped 19.42%. In the past three and six months, the stock has gained 38.75%and 33.67% respectively. Furthermore, CEL-SCI is currently valued in the market at $766.11 million and has 40.53 million outstanding shares.

    Biotech Investors are hinging on the success of Multikine phase 3

    CEL-SCI stock rallied up to 45% this week. The boost is coming due to the gathering of results for the advancement in the phase III trial of its flagship investigational product Multikine.

    On similar news related to Multikine, the company had seen a whopping gain of 82% in the month of January (on 26th) which was correlated with the WallStreetBets rally. Multikine is the only late-stage candidate of CVM stock and the reason behind the surge was the tweet by Geert Kersten – CEO of CEL-SCI which hyped up news about Multikine Phase III data’s release.

    However, the news of the release of data had dragged on even passing the month of February, in which the Kerstentold the investors to keep their head high for the data and have confidence in the stock. Now the hype is aired around the full data analysis readout for the clinical study of immunotherapy. Success of this lead investigative product will lead to a life-changing course of action for patients with squamous cell carcinoma in the head or the neck.

    Where will the success of Multikline lead the company?

    The success of phase III Multikline will move the company to a phase where it can commercialize this treatment and boost the value of the CVM stock. Furthermore, the company will become an attractive buyout candidate for big pharma companies waiting to gain the benefits of its future potential.

    CES-SCI’s lead product offering and operational background

    CEL-SCI Corporation is a biotechnology company that specifically focuses on the design and development of novel treatments that are offered to target the demands and unmet needs of patients with certain diseases. The biotech company aims to develop immunotherapies for the treatment of infectious diseases as well as cancer. The leading investigational immunotherapy of CEL-SCI is Multikine. Multikine is being developed for the treatment of head and neck cancer. The immunotherapy is currently under clinical phase III trial.

    CEL-SCI has also created a T-cell modulation procedure that can trigger the immune system to fight bacterial, parasitic and viral infections. The process is done by the system known as LEAPS which stands for Ligand Epitope Antigen Presentation System. LEAPS also focuses on the countering of autoimmune diseases, cancer, and allergies. The company uses this LEAPS system for a different platform which includes the treatment of rheumatoid arthritis and even a product candidate for coronavirus.

  • Pre-Market Cues: 45 Stocks Roaring for Change On November 16th

    Pre-Market Cues: 45 Stocks Roaring for Change On November 16th

    CBAK Energy Technology Inc. (CBAT) stock soared 51.22% to $9.3 in pre-market trading.
    Asia Pacific Wire & Cable Corporation Limited (NASDAQ: APWC) shares are trading up 9.74% at $2.14 at the time of writing. The company’s 52-week range was noted as $0.89 to $2.69.
    Electra Meccanica Vehicles Corp. (SOLO) grew over 8.9% at $6.85 in pre-market trading today following analyst’s prediction that electric vehicles will overtake the global automotive sector in the near future.
    CPS Technologies Corporation (CPSH), an Electronic Components company, dropped about -8.72% at $1.57 in pre-market trading Monday.
    HighPoint Resources Corporation (HPR) stock moved up 77.39 percent to $6.67 in the pre-market trading after the news that Bonanza Creek Energy, Inc. BCEI and HighPoint Resources Corporation HPR have agreed on a merger worth $376 million.
    Navidea Biopharmaceuticals Inc. (NAVB) lost over -5.8% at $2.6 in pre-market trading Monday 16 November 2020 after the company announced its financial results for the third quarter and year-to-date 2020.
    Hall of Fame Resort & Entertainment Company (HOFV) is down more than -11.65% at $2.2 in pre-market hours Monday 16 November 2020 as the company and the NFL alumni association offered updates on the success of the inaugural NFL alumni academy. The stock had jumped over 22.06% to $2.49 in the last trading session.
    Before the trading started on 16 November 2020, GreenPower Motor Company Inc. (GP) is up 6.98% to reach $13.48 after the company posted its 2nd quarter financial results for 2021. It has been trading in a 52-week range of $0.82 to $23.45.
    Zomedica Pharmaceuticals Corp. (ZOM) stock plunged -7.07% to $0.088 in the pre-market trading as the plans to initiate commercialization on 30 March 2021 of its TRUFORMATM point-of-care diagnostic platform revealed.
    Polar Power Inc. (NASDAQ: POLA) shares are trading up 7.81% at $3.59 at the time of writing. Company’s 52-week range was noted as $0.95 to $6.56.
    Sino-Global Shipping America Ltd. (SINO) tumbled over -2.92% at $2.66 in pre-market trading today.
    Pinduoduo Inc. (PDD), an Internet Retail company, dropped about -1.78% at $148.59 in pre-market trading Monday as the firm unveils its Q3 results.
    Tellurian Inc. (TELL) stock moved down -4.51 percent to $0.9644 in the pre-market trading as the news appeared that the company is pondering new Asia gas deals After Petronet snub.
    9 Meters Biopharma Inc. (NMTR) lost over -3.58% at $0.8 in pre-market trading Monday 16 November 2020 as the company revealed financial results and business updates.
    Centennial Resource Development Inc. (CDEV) is down more than -2.88% at $0.741 in pre-market hours Monday 16 November 2020 after the company said Sean R. Smith, Chief Executive Officer, is set to attend the Bank of America Securities Global Energy Conference to be held virtually on Thursday. The stock had jumped over 9.14% to $0.76 in the last trading session.
    Before the trading started on 16 November 2020, Genius Brands International Inc. (GNUS) is up 7.38% to reach $1.31, after the company stated that it is set to host a conference call at 10:00 a.m. Eastern Time on Monday, November 16, 2020, to review major initiatives underway and recent developments. The stock has been trading in a 52-week range of $0.05 to $11.73.
    CureVac N.V. (CVAC) stock soared 8.38% to $81.5 in the pre-market trading after the report that the covid-19 vaccine could be a drug industry game-changer. The most recent rating by Jefferies, on September 08, 2020, is a Hold.
    Apple Hospitality REIT Inc. (NYSE: APLE) shares are trading down -2.83% at $12.02 at the time of writing after the company posted 3rd quarter results of operation. The company’s 52-week range was noted as $4.48 to $16.42. Analysts have a consensus price target of $13.
    Transocean Ltd. (RIG) tumbled over -3.7% at $1.04 in pre-market trading today as the company stock soared 53% since the earnings announcement.
    Cinedigm Corp. (CIDM), an Entertainment company, rose about 8.33% at $0.65 in pre-market trading Monday as the company has purchased North American distribution rights to 100 DAYS TO LIVE, a taut psychological thriller set in the world of suicide prevention and mental health.
    Range Resources Corporation (RRC) stock moved down -5.57 percent to $6.78 in pre-market trading as the company recently revealed disappointing earnings.
    UP Fintech Holding Limited (TIGR) gained over 11.9% at $6.02 in pre-market trading Monday 16 November 2020 as the capital market giant revealed that it will announce its Q3 results on November 23, 2020.
    Taubman Centers Inc. (TCO) is up more than 8.11% at $42.68 in pre-market hours Monday 16 November 2020 after the publication report that Simon Property and Taubman have finally agreed on a merger on a well-reduced price of $43.00 per share in cash. The stock had jumped over 5.53% to $39.48 in the last trading session.
    Before the trading started on 16 November 2020, Banco Bilbao Vizcaya Argentaria S.A. (BBVA) is up 15.24% to reach $4.31 after the announcement that PNC Financial Services Group Inc (NYSE: PNC) is set to take over Banco Bilbao Vizcaya Argentaria (BBVA) U.S. business in an $11 billion all-cash deal. The stock has been trading in a 52-week range of $2.49 to $5.80.
    Kandi Technologies Group Inc. (KNDI) stock soared 7.62% to $7.77 in the pre-market trading as the Company announced that It completed a registered direct offering of 9,404,392 shares of its securities at a sales price of $6.38 per share, raising about $60,000,000 in net gross proceeds to the Firm before deducting the selling agent’s fees and other expected offering expenditures incurred by the Company.
    Textainer Group Holdings Limited (NYSE: TGH) shares are trading down -5.5% at $15.65 at the time of writing after the company posted its third-quarter results. The company’s 52-week range was noted as $5.50 to $17.33. Analysts have a consensus price target of $18.
    Gulfport Energy Corporation (GPOR) tumbled over -45.61% at $0.13 in pre-market trading today after the company filed for bankruptcy.
    Akerman Corp. (KERN), a Health Information Services company, dropped about -3.46% at $2.79 in pre-market trading Monday after the company posted its earnings results.
    United States Antimony Corporation (UAMY) stock moved up 4.17 percent to $0.375 in the pre-market trading.
    ADiTx Therapeutics Inc. (ADTX) lost over -2.03% at $1.93 in pre-market trading Monday 16 November 2020 as the company offered the latest business updated as well as its fiscal quarterly report.
    Arbutus Biopharma Corporation (ABUS) is up more than 10.19% at $4.0 in pre-market hours Monday 16 November 2020 after the firm revealed presentation of phase 1a/1b clinical trial results for AB-729 in chronic hepatitis B subjects at the liver meeting digital experience, the American Association for the study of Liver Diseases meeting. The stock had jumped over 2.25% to $3.63 in the last trading session.
    Before the trading started on 16 November 2020, Ideanomics Inc. (IDEX) is up 31.31% to reach $1.3 after the company revealed the final agreement to take over Timios holding corps. It has been trading in a 52-week range of $0.28 to $3.98.
    Pacific Ethanol Inc. (PEIX) stock soared 4.71% to $6.0 in the pre-market trading as the company announced Q3 results. The most recent rating by BWS Financial, on September 22, 2020, is a Buy.
    CEL-SCI Corporation (AMEX: CVM) shares are trading up 10.5% at $14.0 at the time of writing. The company’s 52-week range was noted as $6.35 to $18.00. Analysts have a consensus price target of $18.
    AMC Entertainment Holdings Inc. (AMC) grew over 8.42% at $3.22 in pre-market trading today following news that Cinemark joins AMC in pursuing a shortened movie window.
    Sogou Inc. (SOGO), an Internet Content & Information company, dropped about -3.14% at $8.64 in pre-market trading Monday as the company unveiled its Q3, 2020 results.
    ObsEva SA (OBSV) stock moved up 18.84 percent to $2.46 in the pre-market trading as the company announced the positive topline results of PROLONG, the Phase 2a proof-of-concept, randomized, double-blind, placebo-controlled trial of laropiprant in preterm labor.
    Denison Mines Corp. (DNN) lost over -9.3% at $0.32 in pre-market trading Monday 16 November 2020 after the company announced the establishment of the At-The-Market Program.
    Pyxis Tankers Inc. (PXS) is down more than -25.74% at $0.8763 in pre-market hours Monday 16 November 2020 as the company announced results for its 3rd quarter and year to date. The stock had dropped over 0.00% to $1.18 in the last trading session.
    Before the trading started on 16 November 2020, Qutoutiao Inc. (QTT) is down -2.13% to reach $2.3. It has been trading in a 52-week range of $2.12 to $6.55.
    Uxin Limited (UXIN) stock plunged -3.85% to $1.0 in the pre-market trading after the news that the company’s Net Promoter Score (NPS) increases to 30 during the quarter ended September 30, 2020. The most recent rating by JP Morgan, on October 23, 2019, is at a Neutral.
    VistaGen Therapeutics Inc. (NASDAQ: VTGN) shares are trading down -2.13% at $0.6851 at the time of writing. The company’s 52-week range was noted as $0.29 to $1.15. Analysts have a consensus price target of $6.
    Sypris Solutions Inc. (SYPR), an Auto Parts company, dropped about -3.6% at $1.34 in pre-market trading Monday after the company announced its 3rd quarter earnings results.
    Alterity Therapeutics Limited (ATHE) stock moved up 169.57 percent to $3.1 in the pre-market trading.